TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27900179

Group type: EXPERIMENTAL
Intervention: Higher levels of n-PINP (procollagen type I N-terminal propeptide)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Higher levels of n-PIIINP (procollagen type III N-terminal propeptide)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Increased concentrations of PINP
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Increased concentrations of PIIINP
Number of subjects: 65
Study: 27900199

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (225 min/week)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (normal diet maintenance)
Number of subjects: 320
Study: 27900346

Group type: EXPERIMENTAL
Intervention: ZFN-mediated CCR5 disruption in HSPC; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation with naturally occurring homozygous deletion of CCR5 in donor HSPC; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 27900372

Group type: EXPERIMENTAL
Intervention: Marginal structural model with inverse-probability weighting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intention-to-treat results
Number of subjects: 0
Study: 27900579

Group type: EXPERIMENTAL
Intervention: AhR stimulation in MCF-7 cell line
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: AhR stimulation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: AhR agonist treatment
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Correlation analysis of AhR and aromatase status
Number of subjects: 29
Study: 27900953

Group type: EXPERIMENTAL
Intervention: iBCI with velocity decoder and exponential smoothing dynamics
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: iBCI with varied gain (speed scaling) and temporal smoothing parameters
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Control policy model
Number of subjects: 3
Study: 27902470

Group type: EXPERIMENTAL
Intervention: QLNC120
Number of subjects: 24
Study: 27902648

Group type: EXPERIMENTAL
Intervention: Pertussis cases
Number of subjects: 1200000
Study: 27902652

Group type: EXPERIMENTAL
Intervention: PCV13 vaccination
Number of subjects: 200
Study: 27903260

Group type: EXPERIMENTAL
Intervention: Participants who developed resting hypoxemia
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Enrollment at Denver
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Lower baseline oxygen saturation
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Self-reported heart failure
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Pulmonary artery (PA) enlargement on computed tomography
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Prior severe COPD exacerbation
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Participants who developed hypoxemia
Number of subjects: 678
Study: 27903267

Group type: EXPERIMENTAL
Intervention: CT-derived low skeletal muscle quality (assessed by skeletal muscle density)
Number of subjects: 491
Study: 27903416

Group type: EXPERIMENTAL
Intervention: JE-CV (live attenuated Japanese encephalitis vaccine) administered as primary vaccination (Group 1)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: JE-CV (live attenuated Japanese encephalitis vaccine) administered as booster vaccination (Group 2)
Number of subjects: 10000
Study: 27903614

Group type: EXPERIMENTAL
Intervention: Inpatient sleep duration (measured by wrist actigraphy)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Sleep efficiency (measured by wrist actigraphy)
Number of subjects: 212
Study: 27903616

Group type: EXPERIMENTAL
Intervention: hs-TnI cutoff of 3 ng/L with low risk ECG
Number of subjects: 4606

Group type: EXPERIMENTAL
Intervention: Follow-up mortality in ruled out population
Number of subjects: 4606
Study: 27903810

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN DBS)
Number of subjects: 20
Study: 27904503

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived stem cells (BMSCs)
Number of subjects: 0
Study: 27904903

Group type: EXPERIMENTAL
Intervention: WILL-BLEED Risk Score
Number of subjects: 3744

Group type: EXPERIMENTAL
Intervention: Preoperative anaemia
Number of subjects: 3744

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 3744

Group type: EXPERIMENTAL
Intervention: eGFR <45 ml/min/1.73 m²
Number of subjects: 3744
Study: 27904904

Group type: EXPERIMENTAL
Intervention: N8-GP for prophylaxis (50 IU/kg every fourth day)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: N8-GP for on-demand treatment (20-75 IU/kg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: N8-GP overall
Number of subjects: 175
Study: 27906044

Group type: EXPERIMENTAL
Intervention: Heterogeneously dense breasts (50-75% density)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Extremely dense breasts (>75% density)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Positive margins after surgery
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Dense breasts (>50% density) with positive margin, no adjuvant radiotherapy, and no adjuvant chemotherapy
Number of subjects: 242
Study: 27906840

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 1868
Study: 27908594

Group type: EXPERIMENTAL
Intervention: Rucaparib (600 mg twice per day for continuous 28 day cycles)
Number of subjects: 206
Study: 27908600

Group type: EXPERIMENTAL
Intervention: SERT = 0 (no risk factors)
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: SERT scores 1-4 (presence of risk factors)
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Lesion size ≥40 mm
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Bleeding during the procedure
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: High-grade dysplasia
Number of subjects: 1178
Study: 27908843

Group type: EXPERIMENTAL
Intervention: Telemedically-delegated medication by paramedics (study group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Regular EMS missions (control group)
Number of subjects: 150
Study: 27909037

Group type: EXPERIMENTAL
Intervention: Cyberknife with 1 cycle of S-1 simultaneously followed by 2 or 3 cycles of S-1 sequentially
Number of subjects: 190
Study: 27909039

Group type: EXPERIMENTAL
Intervention: RAI-HC assessment
Number of subjects: 437000

Group type: EXPERIMENTAL
Intervention: Proportional hazards regression
Number of subjects: 437000
Study: 27909081

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) monotherapy
Number of subjects: 0
Study: 27911128

Group type: EXPERIMENTAL
Intervention: Docetaxel in combination with oxaliplatin and S-1 (DOS2w)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Docetaxel in combination with oxaliplatin and S-1 (DOS3w)
Number of subjects: 34
Study: 27911591

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) analog treatment
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1
Study: 27912069

Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (Fluarix™ Tetra)
Number of subjects: 120
Study: 27912740

Group type: EXPERIMENTAL
Intervention: In-home respite care program by Baluchon Alzheimer
Number of subjects: 372

Group type: COMPARATOR
Intervention: Standard dementia care (control group)
Number of subjects: 372
Study: 27912744

Group type: EXPERIMENTAL
Intervention: Stroke Specific Quality of Life Scale (SSQOLS)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Severe functional disability
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Hospital admissions
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Severe neurologic pain
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Caregivers' qualitative themes
Number of subjects: 350
Study: 27912784

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg/day) added to metformin (1500-3000 mg/day)
Number of subjects: 121
Study: 27912924

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 1604

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 1604
Study: 27913777

Group type: EXPERIMENTAL
Intervention: Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis
Number of subjects: 150
Study: 27913881

Group type: EXPERIMENTAL
Intervention: S-1 plus oral leucovorin (S-1/LV)
Number of subjects: 39
Study: 27914133

Group type: EXPERIMENTAL
Intervention: Lobeglitazone 0.5 mg once daily for 24 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lobeglitazone
Number of subjects: 50
Study: 27914187

Group type: EXPERIMENTAL
Intervention: Enhanced nutrient supply
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard nutrient supply
Number of subjects: 50
Study: 27914292

Group type: EXPERIMENTAL
Intervention: Low-affinity and low-trapping NMDA receptor antagonists
Number of subjects: 7
Study: 27914468

Group type: COMPARATOR
Intervention: Control group from the Take a Stand! Intervention
Number of subjects: 135
Study: 27914470

Group type: EXPERIMENTAL
Intervention: High CRP level
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Elevated CRP
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Symptom classes
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Systemic biomarkers of inflammation
Number of subjects: 302
Study: 27914502

Group type: EXPERIMENTAL
Intervention: Serial coronary computed tomographic angiography (CCTA)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Follow-up beyond serial CCTA performance
Number of subjects: 2000
Study: 27914861

Group type: EXPERIMENTAL
Intervention: SAFE-IPV intervention
Number of subjects: 98
Study: 27914971

Group type: EXPERIMENTAL
Intervention: Ofatumumab 300 mg during week 1 followed by 1000 mg during weeks 2-4 (Group A)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ofatumumab 300 mg during week 1 and 2000 mg during weeks 2-5 (Group B)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ofatumumab 300 mg during week 1 and 2000 mg during weeks 2-5 (Cycle 2 for responders)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Specific adverse events
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: IgM flare
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 37
Study: 27915408

Group type: EXPERIMENTAL
Intervention: Copanlisib 0.4 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Copanlisib 0.8 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Copanlisib (both doses)
Number of subjects: 10
Study: 27915457

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention using the RASP list and medication review
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (usual geriatric care)
Number of subjects: 172
Study: 27916234

Group type: EXPERIMENTAL
Intervention: Phantom motor execution using machine learning, augmented and virtual reality, and serious gaming (12 sessions)
Number of subjects: 14
Study: 27916627

Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27917531

Group type: EXPERIMENTAL
Intervention: Herpes zoster
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Postherpetic neuralgia
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Other complications
Number of subjects: 412

Group type: COMPARATOR
Intervention: Male sex
Number of subjects: 412

Group type: COMPARATOR
Intervention: Age 70-74 years
Number of subjects: 412

Group type: COMPARATOR
Intervention: Immunosuppressive therapy
Number of subjects: 412

Group type: COMPARATOR
Intervention: Severe herpes zoster pain at first consultation
Number of subjects: 412

Group type: COMPARATOR
Intervention: Rash on upper arms
Number of subjects: 412
Study: 27917600

Group type: EXPERIMENTAL
Intervention: Chronic hepatitis B (e antigen positive)
Number of subjects: 1390

Group type: EXPERIMENTAL
Intervention: Chronic hepatitis B (e antigen negative)
Number of subjects: 1390

Group type: EXPERIMENTAL
Intervention: Inactive carriers
Number of subjects: 1390

Group type: EXPERIMENTAL
Intervention: Indeterminant cases
Number of subjects: 1390

Group type: EXPERIMENTAL
Intervention: Overall categorization of chronic hepatitis B
Number of subjects: 1390
Study: 27918827

Group type: EXPERIMENTAL
Intervention: Glaucoma subjects
Number of subjects: 100

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 100
Study: 27918881

Group type: EXPERIMENTAL
Intervention: QUIT4EVER (mobile contingency management smoking cessation counseling and medications + Stay Quit Coach)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Contact control condition (identical to QUIT4EVER but without Stay Quit Coach)
Number of subjects: 11
Study: 27919055

Group type: EXPERIMENTAL
Intervention: Early intensive blood pressure lowering
Number of subjects: 2756

Group type: EXPERIMENTAL
Intervention: Proxy responders
Number of subjects: 2756

Group type: EXPERIMENTAL
Intervention: Age and comorbidities
Number of subjects: 2756

Group type: EXPERIMENTAL
Intervention: High NIHSS score
Number of subjects: 2756
Study: 27919259

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with Reverdin-Isham and Akin percutaneous osteotomy
Number of subjects: 80
Study: 27919438

Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-obese subjects (control)
Number of subjects: 0
Study: 27919491

Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (DMF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disability worsening
Number of subjects: 0
Study: 27919506

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 25
Study: 27919862

Group type: EXPERIMENTAL
Intervention: NeuroAiD (MLC601) for 6 months in addition to standard care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NeuroAiD (MLC601)
Number of subjects: 0
Study: 27919899

Group type: EXPERIMENTAL
Intervention: Darunavir 800 mg once daily (QD)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Darunavir 600 mg twice daily (BID)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Three-direct-acting antiviral (3D) regimen with ribavirin (RBV)
Number of subjects: 22
Study: 27920519

Group type: EXPERIMENTAL
Intervention: telemonitoring plus education
Number of subjects: 119

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 119
Study: 27920566

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily, Deleobuvir 600 mg twice daily, Ribavirin (weight-based) for 16 weeks (Arm 1)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily, Deleobuvir 600 mg twice daily, Ribavirin (weight-based) for 24 weeks (Arm 2)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily, Deleobuvir 600 mg twice daily, Ribavirin (weight-based) for 24 weeks (Arm 3)
Number of subjects: 208
Study: 27921221

Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg every 4 weeks
Number of subjects: 97
Study: 27921340

Group type: EXPERIMENTAL
Intervention: Exposure therapy (speech exposure session)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Better extinction learning (less negative stimulus ratings)
Number of subjects: 24
Study: 27922747

Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS) score
Number of subjects: 1040
Study: 27923043

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg daily until progression
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg daily and intravenous vinorelbine 25 mg/m2 weekly after progression
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Trastuzumab-naïve patients with somatic activation of PI3K/Akt signalling
Number of subjects: 26

Group type: COMPARATOR
Intervention: Afatinib combined with vinorelbine
Number of subjects: 26
Study: 27923359

Group type: EXPERIMENTAL
Intervention: Sertraline (doses ranged from 12.5 to 150 mg/day, mostly 25 and 50 mg/day)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 122
Study: 27923461

Group type: EXPERIMENTAL
Intervention: Ultrathin strut biodegradable-polymer (BP) sirolimus-eluting stents (SES)
Number of subjects: 2119

Group type: COMPARATOR
Intervention: Durable-polymer (DP) everolimus-eluting stents (EES)
Number of subjects: 2119

Group type: EXPERIMENTAL
Intervention: Complex patients
Number of subjects: 2119
Study: 27923779

Group type: EXPERIMENTAL
Intervention: Multidisciplinary model to guide employment outcomes among PLWSCI
Number of subjects: 0
Study: 27923814

Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sera from acute KD patients
Number of subjects: 0
Study: 27925796

Group type: COMPARATOR
Intervention: Blood analysis and gene expression profiling
Number of subjects: 610

Group type: COMPARATOR
Intervention: Severe asthma subgroup
Number of subjects: 610

Group type: COMPARATOR
Intervention: Pathway analysis
Number of subjects: 610

Group type: COMPARATOR
Intervention: Cluster analysis of DEGs
Number of subjects: 610
Study: 27926445

Group type: EXPERIMENTAL
Intervention: Knowledge of performance after good performance plus a monetary reward
Number of subjects: 0

Group type: COMPARATOR
Intervention: Knowledge of performance after a random selection of trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Knowledge of performance after good performance
Number of subjects: 0
Study: 27926636

Group type: EXPERIMENTAL
Intervention: Fetoscopic tracheal occlusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nontreated historical cohort
Number of subjects: 20
Study: 27926649

Group type: EXPERIMENTAL
Intervention: Expecting excessive gestational weight gain
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Expecting excessive gestational weight gain (adjusted for previous weight gain and sociodemographic characteristics)
Number of subjects: 230
Study: 27926904

Group type: EXPERIMENTAL
Intervention: Text message support for weight loss
Number of subjects: 0
Study: 27926979

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs), median duration of 27.5 months (range 0-77 months)
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs)
Number of subjects: 1696
Study: 27927586

Group type: EXPERIMENTAL
Intervention: RBAC500 (rituximab 375 mg/m2, bendamustine, low-dose cytarabine)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: RBAC500
Number of subjects: 57
Study: 27927609

Group type: EXPERIMENTAL
Intervention: Web-accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Validated population pharmacokinetic (PopPK) models
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Individualized estimates of PK parameters
Number of subjects: 300
Study: 27927635

Group type: EXPERIMENTAL
Intervention: Iodine intake of 200-249 μg/d for children aged 7-10 y
Number of subjects: 2089

Group type: EXPERIMENTAL
Intervention: Iodine intake of 250-299 μg/d for children aged 11-14 y
Number of subjects: 2089

Group type: EXPERIMENTAL
Intervention: Iodine intake ≥150 μg/d
Number of subjects: 2089

Group type: EXPERIMENTAL
Intervention: Iodine intake ≥250 μg/d for children aged 7-10 y
Number of subjects: 2089

Group type: EXPERIMENTAL
Intervention: Iodine intake ≥300 μg/d for children aged 11-14 y
Number of subjects: 2089

Group type: EXPERIMENTAL
Intervention: Iodine intake of 150-249 μg/d for children aged 7-10 y
Number of subjects: 2089

Group type: EXPERIMENTAL
Intervention: Iodine intake of 150-299 μg/d for children aged 11-14 y
Number of subjects: 2089
Study: 27927677

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography (OCTA) with AngioVue
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography (OCTA) with AngioPlex
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluorescein angiography (FA)
Number of subjects: 50
Study: 27927700

Group type: EXPERIMENTAL
Intervention: Cardiac α intervention
Number of subjects: 0
Study: 27927766

Group type: EXPERIMENTAL
Intervention: Rebastinib (DCC-2036) administered at doses from 57 mg to 1200 mg daily (powder-in-capsule) and 100 mg to 400 mg daily (tablet preparations). Maximum tolerated dose was 150 mg tablets administered twice daily.
Number of subjects: 57
Study: 27928583

Group type: EXPERIMENTAL
Intervention: Hypoxic hepatitis (HH)
Number of subjects: 172

Group type: COMPARATOR
Intervention: No hypoxic hepatitis (HH)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Aspartate-aminotransferase (ASAT)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: New biomarkers (argininosuccinate synthase 1 and sulfotransferase isoform SULT2A1)
Number of subjects: 172
Study: 27928641

Group type: EXPERIMENTAL
Intervention: Baseline dental assessment
Number of subjects: 2294

Group type: COMPARATOR
Intervention: None to mild plaque, calculus, gingivitis, or periodontal disease
Number of subjects: 2294

Group type: EXPERIMENTAL
Intervention: Severe dental conditions (poor oral hygiene)
Number of subjects: 2294
Study: 27928738

Group type: EXPERIMENTAL
Intervention: Clarithromycin 1000 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vonoprazan 40 mg
Number of subjects: 16
Study: 27929312

Group type: EXPERIMENTAL
Intervention: 2-session adolescent program with an additional parent session (BI-AP)
Number of subjects: 259

Group type: COMPARATOR
Intervention: 2-session adolescent-only program (BI-A)
Number of subjects: 259
Study: 27930357

Group type: EXPERIMENTAL
Intervention: High adenosine dose (200 μg/kg per minute)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard adenosine dose (140 μg/kg per minute)
Number of subjects: 30
Study: 27930660

Group type: EXPERIMENTAL
Intervention: P. vivax infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: P. falciparum infection
Number of subjects: 0
Study: 27931196

Group type: EXPERIMENTAL
Intervention: Active attentional bias training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Yoked-control group
Number of subjects: 32
Study: 27931243

Group type: EXPERIMENTAL
Intervention: Pacritinib 400 mg QD
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pacritinib 100 to 600 mg QD
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pacritinib 500 mg QD
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pacritinib
Number of subjects: 74